ClinicalTrials.gg
Not yet recruitingNCT06973603POPENDOUpdated Sep 16, 2026

Exposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort

An observational study in Endometriosis, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.

Planned enrollment
10th of 58
650 · median 133
Started
2026
with 14 others
Observational
58 of 128
23 open now
Primary completion
2026-12
later than 17 of 55 live
Registered
103rd of 128
by date

Among the 128 studies in Endometriosis with a site in France, this one is the 10th largest by planned enrollment of the 58 observational ones that give a count, is one of 15 that started in 2026, is one of 58 observational ones, reaches primary completion later than 17 of the 55 other live ones, and was the 103rd registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometriosis with a site in France, or all of them as a file.
02

Study summary

Endometriosis is a chronic inflammatory disease affecting \~10% of women of childbearing age. It is characterized by the presence of endometrial-like tissue outside the uterus, causing lesions and adhesions between the organs, and is often accompanied by intense pain and sometimes infertility. The four-stage classification based on the severity of lesions does not always reflect the severity of symptoms. Adenomyosis, a similar pathology, is often present in the same patients, although it is now considered distinct from endometriosis. Diagnosis usually takes a long time, with an average delay of 7 years. The cause of the disease remains unknown, but hormonal, genetic and environmental factors, such as exposure to endocrine disruptors, are suspected. Persistent organic pollutants (POPs), such as dioxins and PCBs, may influence the risk and severity of the disease. Although experimental studies suggest a link between these substances and the progression of endometriosis, epidemiological research on the subject is still limited.

The central hypothesis of the POPENDO project is that higher concentrations of persistent organic pollutants (POPs) are associated with increased severity of endometriosis. The aim of the study is to explore the associations between serum levels of four families of POPs (PCBs, organochlorine pesticides, PFAS and BFR) and endometriosis.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • exposition
  • Endometriosis
  • Organic Persistent Polluant
  • Endometriosis severity
  • endomestriosis symptoms
  • endometriosis pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population will be a group of female volunteers who have self-reported endometriosis. The group size will be a random sample of 650 women from the \~10,000 participants included in the ComPaRe-Endometriosis sub-cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ComPaRe participants ⩾ 18 years old. All ComPaRe participants are at least 18 years of age, so our research participants will all be adults.
  • Having declared in ComPaRe that they had endometriosis
  • Living in the Ile-de-France region (departments 75, 77, 78, 91, 92, 93, 94 or 95);
  • Have given electronic consent stating: "By checking this box, I agree to be solicited for research outside ComPaRe"; This criterion is collected at the time of ComPaRe registration, when consent is collected. Participants can withdraw this consent at any time on their secure personal online account on the ComPaRe platform.
  • Aged ≤ 45 years to avoid including premenopausal or menopausal women;
  • In possession of MRI images used to diagnose their endometriosis (CD-ROM) that are no more than 5 years old;
  • Enrolled in or benefiting from a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • - People with to blood sampling will not be included in this research:
  • Known severe anemia
  • Hemophilia/coagulation disorders/anticoagulant use
  • People with , or will not be included in this study due to the risk of BSE (Blood Exposure Accident).
  • Based on factors that may disrupt lipid dynamics and lipid pollutants, the following individuals will not be included:
  • Pregnant and breast-feeding women
  • People suffering from any of the following diseases:

    • Cancer
    • Morbid obesity (>40)
    • Non-alcoholic steatohepatitis (NASH)
  • Persons under court protection/guardianship/guardianship will not be able to participate in this research.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherBlood samples

    24mL blood sample (3 dry tubes with 8mL)

06

What researchers measure

Primary outcomes

  1. Assessment of the severity of endometriosis, defined by the type of disease.

    Analysis of several online questionnaires on endometriosis by participants

    Time frame: During 3 last years of analysis

  2. Evaluation of serum levels of polychlorinated biphenyls (PCBs)

    Chemical analysis of participants' blood samples by the LABERCA laboratory

    Time frame: 5 months after inclusion start until analysis of the last participant' blood sample

  3. Evaluation of serum levels of per- and polyfluoroalkylates (PFAS)

    Chemical analysis of participants' blood samples by the LABERCA laboratory

    Time frame: 5 months after inclusion start until analysis of the last participant' blood sample

  4. Evaluation of serum levels of Brominated flame retardants polluent (BFRs)

    Chemical analysis of participants' blood samples by the LABERCA laboratory

    Time frame: 5 months after inclusion start until analysis of the last participant' blood sample

  5. Evaluation of serum levels of organochlorine pesticides (POCs)

    Chemical analysis of participants' blood samples by the LABERCA laboratory

    Time frame: 5 months after inclusion start until analysis of the last participant' blood sample

Secondary outcomes

  1. definition of the level of severity of endometriosis by the rASRM stage (revised stage of the American Society for Reproductive Medicine)

    Analysis of online questionnaires on endometriosis and rASRM stage

    Time frame: During 3 last years of analysis

  2. definition of the level of severity of endometriosis by the anatomical extension of the disease observed on MRI

    Pelvic MRI images will be reviewed by radiologists from Hôpital Paris Saint Joseph to map endometriosis across 21 anatomical structures within 5 pelvic segments, using the ENZIAN classification to assess lesion location and severity.

    Time frame: During 3 last years of analysis

  3. endometriosis severity level defined by the severity of painful symptoms.

    Analysis of annual follow-up questionnaire of ComPaRe-Endometriosis study participant assessing the severity of various pain types over the past three months using a numeric rating scale.

    Time frame: During 3 last years of analysis

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 0 months is below that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 15, 2025
StartEst.
Dec 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973603
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Dec 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 16, 2026

Study contacts

Frédérique Perrotte, Principal investigator
Contact
fperrotte@ghpsj.fr
01 44 12 38 31
MARINA Kvaskoff, Dr
study director · Hôpital Paul Brousse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion